As NET patients, some of us with extended metastasis, are we all more vulnerable to the virus than the average population? Featured


This is not entirely known but cancer patients may be at higher risk especially if immunocompromised. Certain cancer treatments may increase your risk for immunocompromise and lowering of white blood counts – such as chemotherapy (like platinum/etoposide used for G3 NECs and Capecitabine/Temozolomide used for metastatic pNETs), 177Lu-Dotatate (, Lutathera), everolimus, and sunitinib. Octreotide and Lanreotide do not increase your risk for immunocompromise. If you are receiving treatment for your NET, please discuss the pros and cons of continuing vs. discontinuing treatment with your oncologist. In addition, patients over the age of 60 and those with serious chronic medical conditions like heart disease, diabetes, and lung disease appear to be at higher risk for more serious complications associated with COVID-19.

Posted 2 years agoby globeseek